Richard Pena-Ariet, MD
Internal Medicine · Port Saint Lucie, FLNPI 1225015852
Payments from drug & device makers
Across 431 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$508
- AbbVie$507
- Lilly USA, LLC$488
- GSK$475
- Bayer$442
- plus $4K from 32 others
What the payments were for
- Food & beverage$7,34599%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 73 | $1,044 |
| AstraZeneca | 26 | $508 |
| AbbVie(2 entities) | 31 | $507 |
| Lilly USA, LLC | 29 | $488 |
| GSK | 28 | $475 |
| Bayer | 27 | $442 |
| Amgen | 24 | $414 |
| Sanofi-aventis U.S. LLC | 16 | $272 |
| Abbott | 13 | $251 |
| Novartis | 14 | $232 |
| Dexcom, Inc. | 14 | $229 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $225 |
| Johnson & Johnson | 11 | $224 |
| Sumitomo Pharma America, Inc. | 8 | $216 |
| Astellas Pharma US Inc | 8 | $185 |
| Esperion Therapeutics, Inc. | 11 | $178 |
| Pfizer | 10 | $173 |
| Amarin Pharma, Inc. | 8 | $132 |
| Merck | 8 | $121 |
| Lundbeck LLC | 6 | $121 |
| Exact Sciences | 6 | $119 |
| Boehringer Ingelheim | 6 | $111 |
| Mannkind Corporation | 5 | $99 |
| Idorsia Pharmaceuticals US Inc | 5 | $92 |
| Kowa Pharmaceuticals America, Inc. | 5 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $89 |
| Arbor Pharmaceuticals, Inc. | 5 | $83 |
| Mylan Specialty L.p. | 4 | $74 |
| Paratek Pharmaceuticals, Inc. | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Medtronic | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Biogen | 1 | $15 |
| Almatica Pharma LLC | 1 | $12 |
How this compares
$7,421 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 98 | $113,338 |
| EliquisApixaban | 102 | $112,802 |
| JardianceEmpagliflozin | 63 | $99,944 |
| OzempicSemaglutide | 63 | $78,975 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $70,231 |
| RybelsusSemaglutide | 36 | $64,314 |
| XareltoRivaroxaban | 49 | $53,532 |
| MyrbetriqMirabegron | 46 | $45,704 |
| TrulicityDulaglutide | 29 | $44,128 |
| JanuviaSitagliptin Phosphate | 23 | $37,600 |
| FarxigaDapagliflozin Propanediol | 36 | $34,437 |
| Repatha SureclickEvolocumab | 22 | $29,336 |
| ProliaDenosumab | 15 | $25,913 |
| EntrestoSacubitril/Valsartan | 14 | $23,044 |
| KerendiaFinerenone | 14 | $22,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $488 | $157,466127 claims |
| Novo NordiskOzempic, Rybelsus | $1,044 | $143,28899 claims |
| PfizerEliquis, Premarin | $173 | $120,419120 claims |
| Boehringer IngelheimJardiance | $111 | $99,94463 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $475 | $84,34082 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $508 | $68,88694 claims |
| Johnson & JohnsonXarelto | $224 | $53,53249 claims |
| MerckJanuvia, Belsomra | $121 | $46,09941 claims |
| Astellas Pharma US IncMyrbetriq | $185 | $45,70446 claims |
| AmgenProlia | $414 | $25,91315 claims |
| NovartisEntresto | $232 | $23,04414 claims |
| BayerKerendia | $442 | $22,25514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Port Saint Lucie
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.